National Australia Bank (NAB)

Size: px
Start display at page:

Download "National Australia Bank (NAB)"

Transcription

1 29 March 2016 Analyst TS Lim Authorisation Chris Savage Recommendation Buy (unchanged) Price $25.62 Target (12 months) $29.50 (unchanged) Expected Return Capital growth 15.1% Dividend yield 7.7% Total expected return 22.8% Company Data & Ratios Enterprise value Market cap n/m $67,746m Issued capital 2,644m Free float 100% Avg. daily val. (52wk) $209.5m 12 month price range $ $37.75 GICS sector Price Performance Banks (1m) (3m) (12m) Price (A$) Absolute (%) Rel market (%) National Australia Bank (NAB) And the rest, as they say, is history Re-rating potential supports current valuation NAB s days as the perennial banking underdog could be over following the successful CYB demerger/ipo. All legacy issues have now been sorted out but the bank has yet to realise its full share price potential. While this is partly due to a range of sector specific noise, we believe this should not be the case as NAB s underlying fundamentals and core ROE outlook have never been stronger. As well, NAB has already undergone the best credit de-risking process since the GFC in our view. Since the 2011 announcement of its UK strategic review, NAB has closely tracked a composite group of peers made up of financials that were previously in need of significant restructuring (AMP, MQG and SUN) up until the end of April It significantly deviated from that track following announcements to raise capital and demerge and IPO CYB in May Having established that NAB s core fundamentals are sound, we attribute its underperformance to risks associated with executing the UK transaction. The latter has been successfully concluded and analysis of peer group restructuring outcomes suggests our current valuation will be well supported (with medium term upside in the $ per share range). $29.50 price target and Buy rating maintained In light of last week s credit quality disclosures by ANZ and WBC, we have taken the opportunity to revise NAB s BDD estimates to more realistic levels. Assuming some exposure to single names and lower Institutional write-backs and recoveries, near term BDD charges as a percentage of GLA are increased by 4-5bp to 19-22bp and outer year charges are increased by 3bp to around 24bp. While this would lead to 2-3% lower cash earnings across the forecast horizon, the $29.50 price target is maintained given the benefit of six months time creep in the DCF and blended valuations. NAB is no longer burdened with legacy issues, having successfully completed its de-risking process with the recent demerger and IPO of CYB. The bank is now well positioned to finally bridge the performance gap with its peers and the Buy rating is maintained. Absolute Price $42 $37 $32 $27 $22 Mar 14 Jul 14 Nov Mar Jul 15 Nov NAB S&P 300 Rebased Earnings Forecast Year end 30 September 2015 (pf) 2016e 2017e 2018e NPAT (reported) (A$m) 6,879 5,370 6,748 7,196 NPAT (adjusted) (A$m) 6,457 6,440 6,688 7,136 EPS (adjusted) (A ps) EPS growth (%) 14% -7% 1% 5% PER (x) P/Book (x) P/NTA (x) Dividend (A ps) Yield (%) 7.7% 7.7% 7.7% 7.7% ROE (%) 14.2% 13.9% 13.7% 13.8% NIM (%) 1.82% 1.81% 1.80% 1.79% Franking (%) 100% 100% 100% 100% SOURCE: IRESS SOURCE: BELL POTTER SECURITIES ESTIMATES BELL POTTER SECURITIES LIMITED ACN AFSL DISCLAIMER AND DISCLOSURES THIS REPORT MUST BE READ WITH THE DISCLAIMER AND DISCLOSURES ON PAGE 10 THAT FORM PART OF IT. Page 1

2 And the rest, as they say, is history Re-rating potential supports current valuation Clydesdale s successful demerger and IPO suggest NAB s days as the perennial banking underdog could be over. The bank s legacy issues have been sorted out now but we feel its share price is yet to fully reflect the full upside potential including improved risk/return settings across the business. We revisit AMP s 2003 UK demerger in this note and believe this provides a good indication of where NAB s valuation upside should lie. The catalyst for AMP s share price re-rating was largely the decision to withdraw from the UK and this was despite a $1.7bn capital raising and $1.2bn rights offer (Figure 1). Figure 1 Impact of AMP s UK demerger and IPO Share price $18 $16 $14 $12 $10 $8 $6 $4 $2 $0 Integrates 3 UK brands into AMP UKFS Director retirement (Hewson) Announces next phase of UK restructure Director appointment (Wilcox); MD/CEO appointment (Mohl replaces Batchelor) and senior management restructure; $1bn UK capital support provided by Group AMP de-risking timeline Shareholders approve Australian/UK split into AMP and HHG; director appointment (Yates); organisational change AMP announces intention to withdraw from UK and $1.7bn capital raising Director retirements (Wallis, Cross); director appointments (Handley, Hellicar); Wilcox appointed Chairman AMP $1.2bn rights offer to redeem RPS Director retirements (Bates, Mazoudier, Renard); director appointments (Scheinkestek, Mason) HHG demerged from AMP (AMP stake diluted to 15%); director retirements (Yates, Lord Killearn) reducing Board numbers from 9 to 7 HHG sells 50% stake in Virgin Money $750m capital return from sale of Virgin Money stake $1bn capital returned from sale of HHG stake AMP sells remaining 15% stake in HHG, proposes capital return 2Q01 4Q01 2Q02 4Q02 2Q03 4Q03 2Q04 4Q04 2Q05 4Q05 2Q06 4Q06 2Q07 4Q07 SOURCE: BLOOMBERG, COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Figure 2 Impact of NAB s UK demerger and IPO $40 NAB de-risking timeline $35 New CEO appointed Sale of 80% of MLC Life Share price $30 $25 Post GFC: Announces additional $830m CDO provisions Proposes AXA AP acquisition AXA AP acquisition knocked back by ACCC twice, terminated UK bank capital increased, stategic review commenced 5.6bn noncore UK CRE assets transferred to Group $5.5bn capital raising, GWB IPO, UK demerger & IPO proposed, UK CRE runoff completed $20 Capital raising ($3bn and $2.7bn), acquires Aviva UK CRE runoff: 4.4bn (78% of original balance) UK CRE runoff: 3.3bn (59% of original balance) UK CRE runoff: 2.2bn (39% of original balance) UK demerger & IPO complete Ongoing UK conduct costs $15 2Q08 4Q08 2Q09 4Q09 2Q10 4Q10 2Q11 4Q11 2Q12 4Q12 2Q13 4Q13 2Q14 4Q14 2Q15 4Q15 SOURCE: BLOOMBERG, COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Page 2

3 The rerating has yet to crystallise for NAB (Figure 2) and we believe this is due to specific and systemic events that were not present in AMP s time. These include negative sentiment over further higher capital requirements, ensuing uncertainty over dividend sustainability, unfounded housing bubble fears and negative BDD sentiment following ANZ s disclosures last week. NAB s December quarterly update highlighted no issues with capital adequacy (5.4% leverage ratio ahead of APRA s 3-5% range and the best among the majors so far) and asset quality. Although provisions will likely tick up based on some resource-related and corporate exposures, our recent Bank Note$ suggested NAB of the majors has already undergone the best credit de-risking process since the GFC. The share price performances for AMP/HGG were positive two months after the demerger (Figure 3, and likewise the respective market values in Figure 4) and this re-rating would only be expected from NAB/CYB. Figure 3 AMP/HGG pre- and post-demerger $6.00 AMP/HGG at time of demerger $0.30 $5.00 AMP $1.2bn rights offer to redeem RPS AMP rights offer Institutional bookbuild HHG demerged from AMP (AMP stake diluted to 15%) $0.25 $4.00 Closing date for AMP rights offer $0.20 $3.00 AMP announces intention to withdraw from UK and $1.7bn capital raising through Institutional offer and SPP to facilitate demerger AMP shares commence trading on ASX ex-entitlement New AMP shares from rights offer issued Commencement of normal trading for HGG securities on ASX $0.15 $ Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar-04 AMP (LHS) HGG (RHS) $0.10 Figure 4 AMP/HGG combined valuation pre- and post-demerger excluding rights offer 10,000 Value of AMP and HGG pre- and post-demerger 9,000 8,000 ($m) 7,000 6,000 5,000 AMP $1.2bn rights offer to redeem RPS AMP $1.2bn rights offer shares issued, RPS redeemed Commencement of normal trading for HGG securities on ASX AMP announces intention to withdraw from UK and $1.7bn capital raising through Institutional offer and SPP to facilitate demerger 4, Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar-04 AMP HGG Page 3

4 Although early days, Figures 5 and 6 now imply sentiment has finally turned positive for NAB (although not as rapid as we would have liked). Figure 6 further suggests NAB has continued to trail in terms of share price performance when it first announced the UK demerger and IPO. All else being equal and based on inspection, a fair market value at this point should have been around $79bn or close to our $29.50 per share valuation at the minimum. Figure 7 on the next page suggests no benefit has yet been attributed to NAB s successful UK de-risking, with all the majors having had similar share price movements since May Figure 5 NAB/CYB pre- and post-demerger NAB/CYB at time of demerger $36.00 $4.20 $32.00 $4.00 $28.00 $5.5bn capital raising, GWB IPO, UK demerger & IPO proposed, UK CRE runoff completed, UK conduct costs capped Sale of 80% of MLC Life $3.80 $24.00 $3.60 UK demerger & IPO approved by shareholders Commencement of normal trading for CYB securities on ASX $ May Jun Jul Aug Sep Oct Nov Dec Jan Feb-16 NAB (LHS) CYB (RHS) $3.40 Figure 6 NAB/CYB combined valuation pre- and post-demerger excluding rights offer 90,000 Value of NAB and CYB pre- and post-demerger 85,000 80,000 ($m) 75,000 70,000 $5.5bn capital raising, GWB IPO, UK demerger & IPO proposed, UK CRE runoff completed, UK conduct costs capped Sale of 80% of MLC Life 65,000 60, May Jun Jul Aug Sep Oct Nov Dec Jan Feb-16 NAB CYB UK demerger & IPO approved by shareholders Commencement of normal trading for CYB securities on ASX Page 4

5 Figure 7 NAB share price reaction since start of de-risking initiative vs. major bank peers 1.2 NAB relative performance since start of de-risking initiative Share price indexed to start of NAB de-risking initiative May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar-16 NAB ANZ CBA WBC Figure 8 charts NAB s share price progress since the 2011 announcement of its UK strategic review against a composite group made up of financials that were previously in need of significant restructuring (AMP, MQG and SUN). Not surprisingly, NAB closely tracked the composite index until the end of April 2015 when it has underperformed ever since after having raised $5.5bn in capital and proposed the UK demerger and IPO in May 2015 and being caught up in too much noise from negative capital requirement sentiment and uncertainties over dividend sustainability, asset quality and house prices. A better way to gauge NAB s share price potential would be to have the announcement of the UK demerger and IPO as the starting point (Figure 9, next page). This has narrowed the gap expectations and a fair valuation would be around $ per share. We also estimate the medium term upside could be in the $ per share range. Figure 8 Share price reaction since UK strategic review announcement vs. composite 2.4 NAB's tranformation potential post major initiative announcement 1 Share price indexed to start of de-risking initiative Q+1 Q+2 Q+3 Q+4 Q+5 Q+6 Q+7 Q+8 Q+9 Q+10 Q+11 Q+12 Q+13 Q+14 Q+15 Q+16 Q+17 Q+18 Q+19 Composite NAB Page 5

6 Figure 9 Share price reaction since UK demerger/ipo announcement vs. composite 2.4 NAB's tranformation potential post major initiative announcement 2 Share price indexed to start of de-risking initiative Q+1 Q+2 Q+3 Q+4 Q+5 Q+6 Q+7 Q+8 Q+9 Q+10 Q+11 Q+12 Q+13 Q+14 Q+15 Q+16 Q+17 Q+18 Q+19 Composite NAB $29.50 price target and Buy rating maintained In light of last week s credit quality disclosures by ANZ and WBC, we have taken the opportunity to revise NAB s BDD estimates to more realistic levels. Assuming some exposure to single names and lower Institutional write-backs and recoveries, near term BDD charges as a percentage of GLA are increased by 4-5bp to 19-22bp and outer year charges are increased by 3bp to around 24bp. While this would lead to 2-3% lower cash earnings across the forecast horizon, the $29.50 price target is maintained given the benefit of six months time creep in the DCF and blended valuations. NAB is no longer burdened with legacy issues, having successfully completed its de-risking process with the recent demerger and IPO of CYB. The bank is now well positioned to finally bridge the performance gap with its peers and the Buy rating is maintained. Table 1 Estimate changes NAB 2016e 2017e 2018e 2019e Y/e September 30 ($m) Current Previous Change Current Previous Change Current Previous Change Current Previous Change Profit & Loss Net interest income 13,220 13,234 0% 13,884 13,896 0% 14,577 14,591 0% 15,310 15,324 0% Other income 4,763 4,768 0% 5,045 5,049 0% 5,346 5,350 0% 5,669 5,673 0% Total operating income 17,983 18,002 0% 18,929 18,945 0% 19,923 19,941 0% 20,979 20,997 0% Operating expenses -7,637-7,644 0% -7,996-8,002 0% -8,238-8,245 0% -8,534-8,540 0% Impairment expenses -1, % -1,295-1,044-19% -1,414-1,203-15% -1,542-1,320-14% Net profit before income tax 9,313 9,607-3% 9,638 9,899-3% 10,271 10,493-2% 10,903 11,137-2% Corporate tax expense -2,756-2,844 3% -2,849-2,927 3% -3,035-3,101 2% -3,219-3,289 2% Distributions & other n/m n/m n/m n/m NPAT (cash basis) 6,440 6,646-3% 6,688 6,871-3% 7,136 7,291-2% 7,583 7,747-2% DPS (cps) % % % % EPS (cash basis) (cps) % % % % ROE 13.9% 14.3% -0.4% 13.7% 14.0% -0.3% 13.8% 14.0% -0.2% 13.9% 14.0% -0.1% NIM 1.81% 1.81% 0.00% 1.80% 1.80% 0.00% 1.79% 1.79% 0.00% 1.78% 1.78% 0.00% Cost ratio 42% 42% 0% 42% 42% 0% 41% 41% 0% 41% 41% 0% Impairment expense as % of GLA 0.19% 0.14% -0.05% 0.22% 0.18% -0.04% 0.23% 0.20% -0.03% 0.24% 0.21% -0.03% SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Page 6

7 National Australia Bank Company description NAB is a well-diversified financial services organisation providing a comprehensive range of retail and wholesale banking and wealth management products and services. The bank largely operates in Australia (under the NAB and MLC brands) and in New Zealand (under the BNZ brand) and remains a leader in SME/business banking. Investment strategy NAB s turnaround and de-risking phase is largely complete following the demerger and IPO of CYB. The bank is now focused on the lower risk, capital efficient domestic financial services market space. Our investment strategy is predicated upon NAB improving its NIM (through repricing and pricing discipline), maintaining tight cost management and lifting its overall ROE to levels that are closer to those of its major bank peers (i.e. of 14-15%). Valuation Our price target is roughly based on a blend of DCF, sustainable dividend yield play, sustainable ROE and fully de-risked SOP valuation weighted as follows (with a heavier weighting on the former two as the bank de-risks its UK and US operations and normalises its ROE outlook towards 14-15% in the long term). Table 2 NAB SOP valuation Sum-of-Parts (As Is) 2017e NPAT Pros. PE (times) SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Value ($m) Per NAB share Australia Banking 5, ,308 $24.32 UK (as is) $0.00 Wholesale (in Australia Banking) $0.00 Wealth ,962 $1.88 NZ ,361 $3.16 Other including distributions $0.00 Total 6, ,630 $29.36 Table 3 NAB composite valuation Composite Valuation Value ($m) Per NAB share SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Weighting Composite value per NAB share DCF 75,723 $ % $11.45 Dividend yield (sustainable) 80,345 $ % $12.15 ROE (sustainable) 76,220 $ % $2.88 Sum-of-Parts 77,630 $ % $2.94 Total $29.43 SWOT analysis Strengths 1. Agribusiness and SME / commercial banking capabilities; 2. Highest proportion of investment grade exposures in the sector; 3. Lowest exposure to mining and energy; 4. High quality mortgage loan book; 5. Well diversified geographically; 6. Management execution; and 7. Cost discipline and ROE focus. Weaknesses 1. NIM still soft in business lending; and 2. Market share loss in SME/business banking segments. Page 7

8 Opportunities 1. Further domestic banking and wealth management opportunities based on securing alternate distribution strategies; and 2. Driving the Personal and Business Banking cost ratio to below 35%. Threats 1. Macroeconomic factors, e.g. unemployment and slowing credit growth; 2. Changes in regulatory environment, especially higher liquidity/capital/funding constraints under proposed global regulatory reforms, and the potential capping of funds management and advice fees that would crimp wealth management earnings growth; and 3. Increased competition specifically from the majors and disruptors on the domestic front in retail and wholesale banking and wealth management. Sensitivities Table 4 NAB sensitivities Y/e September e 2017e 2018e 2019e 2020e 2021e 2022e 2023e 2024e Sensitivities Group NIM +10bp NPAT upside (cash basis) 8.0% 8.1% 8.0% 7.9% 8.0% 8.0% 8.0% 8.1% 8.1% - Price target upside $2.35 $2.39 $2.36 $2.34 $2.35 $2.36 $2.37 $2.38 $2.39 Group Loans +1% NPAT upside (cash basis) 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% - Price target upside $0.18 $0.18 $0.18 $0.18 $0.18 $0.18 $0.18 $0.18 $0.18 Australian loans +1% NPAT upside (cash basis) 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.7% - Price target upside $0.24 $0.24 $0.23 $0.23 $0.23 $0.22 $0.22 $0.22 $0.22 NZ loans +1% NPAT upside (cash basis) 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% - Price target upside $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 Other income +1% NPAT upside (cash basis) 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.6% - Price target upside $0.15 $0.16 $0.15 $0.15 $0.16 $0.16 $0.16 $0.16 $0.16 BDD +1% NPAT upside (cash basis) -0.1% -0.1% -0.1% -0.1% -0.1% -0.2% -0.2% -0.2% -0.2% - Price target upside -$0.03 -$0.04 -$0.04 -$0.04 -$0.04 -$0.05 -$0.05 -$0.05 -$0.05 Costs +1% NPAT upside (cash basis) -0.8% -0.8% -0.8% -0.8% -0.8% -0.8% -0.8% -0.8% -0.8% - Price target upside -$0.24 -$0.25 -$0.24 -$0.23 -$0.23 -$0.23 -$0.23 -$0.23 -$0.23 SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES Page 8

9 National Australia Bank as at 29 March 2016 Recommendation Buy Price $25.62 Target (12 months) $29.50 National Australia Bank (NAB) 29 March 2016 Table 5 Financial summary National Australia Share Price (A$) As at 29-Mar-16 Market Cap (A$M) 67,746 PROFIT AND LOSS VALUATION DATA Y/e September 30 ($m) 2014 (pf) 2015 (pf) 2016e 2017e 2018e Y/e September (pf) 2015 (pf) 2016e 2017e 2018e Net interest income 12,062 12,497 13,220 13,884 14,577 NPAT (cash basis) ($m) 5,401 6,457 6,440 6,688 7,136 Other banking income 3,305 3,422 3,520 3,702 3,895 EPS (statutory basis) (cps) Total banking income 15,367 15,919 16,740 17,586 18,473 - Growth 1% 20% -27% 23% 5% Funds management income 1,082 1,091 1,139 1,230 1,328 EPS (cash basis) (cps) Insurance income Growth -8% 14% -7% 1% 5% Total operating income 16,773 17,486 17,983 18,929 19,923 P / E ratio (times) Operating expenses -7,992-7,448-7,637-7,996-8,238 P / Book ratio (times) Impairment expenses ,033-1,295-1,414 P / NTA ratio (times) Net profit before income tax 8,056 9,289 9,313 9,638 10,271 Net DPS (cps) Corporate tax expense -2,509-2,676-2,756-2,849-3,035 Yield 7.7% 7.7% 7.7% 7.7% 7.7% Minority interests Franking 100% 100% 100% 100% 100% Investment experience Payout (cash basis) 87% 76% 82% 81% 78% Distributions & other NPAT (cash basis) 5,401 6,457 6,440 6,688 7,136 CAPITAL ADEQUACY Adjustments , Y/e September (pf) 2015 (pf) 2016e 2017e 2018e NPAT (statutory basis, continuing) 5,526 6,879 5,370 6,748 7,196 Risk weighted assets ($m) 367, , , , ,267 Average risk weight 44% 41% 46% 46% 46% CASHFLOW Tier 1 ratio 10.8% 12.1% 11.5% 11.6% 11.7% Y/e September 30 ($m) 2014 (pf) 2015 (pf) 2016e 2017e 2018e Core Tier 1 ratio 8.6% 9.8% 9.6% 9.8% 10.0% NPAT (cash basis) 5,401 6,457 6,440 6,688 7,136 Total capital ratio 12.2% 13.6% 12.8% 12.9% 12.9% Equity ratio 5.4% 5.7% 5.6% 5.7% 5.7% Increase in loans -16,542-36,721-26,108-26,754-28,507 Increase in other assets -51,483 28,689-6,813-19,082-20,540 DIVISIONAL Capital expenditure Y/e September 30 ($m) 2014 (pf) 2015 (pf) 2016e 2017e 2018e Investing cashflow -67,984-7,584-32,966-45,883-49,096 Australian Banking Net interest income 10,277 10,727 11,433 12,045 12,680 Increase in deposits & borrowings -19,856 23,369 25,048 27,252 29,447 Other income 2,640 2,681 2,665 2,828 3,002 Increase in other liabilities 91,755-28,382 6,303 15,758 16,411 Total banking income 12,917 13,408 14,098 14,874 15,682 Equity raised 436 6,271 1,388 1,428 1,456 Operating expenses -5,267-5,558-5,711-6,060-6,431 Other -4,384-9,739-6,212-5,244-5,355 Impairment expenses ,158-1,272 Financing cashflow 67,951-8,481 26,527 39,195 41,960 Net profit before tax 6,909 7,185 7,527 7,656 7,979 Corporate tax expense -1,962-2,074-2,258-2,297-2,394 Net change in cash 5,368-9, NPAT (cash basis) 4,947 5,111 5,269 5,359 5,585 Cash at end of period 41,034 31,426 31,426 31,426 31,426 Home loans 249, , , , ,585 Other loans 174, , , , ,366 BALANCE SHEET Deposits 299, , , , ,877 Y/e September 30 ($m) 2014 (pf) 2015 (pf) 2016e 2017e 2018e Cash and liquid assets 41,034 31,426 31,426 31,426 31,426 UK Banking Divisional gross loans 481, , , , ,841 Net interest income Provisions -3,118-3,520-3,983-4,193-4,417 Other income Other gross loans / inter div. -19,817-22,392-24,489-25,330-26,171 Total banking income Other IEA 276, , , , ,629 Operating expenses Intangibles 7,720 6,774 6,774 6,774 6,774 Impairment expenses PP&E 1,952 1,504 1,549 1,596 1,645 Net profit before tax Insurance assets 85,032 89,350 80,000 81,600 83,232 Corporate tax expense Other assets 12,431 58,318 58,318 58,318 58,318 NPAT (cash basis) Total assets 883, , , ,180 1,008,276 Home loans Other loans Divisional deposits 338, , , , ,776 Deposits Other borrowings 393, , , , ,792 Other liabilities 102, , , , ,031 NAB Wealth Total liabilities 835, , , , ,600 Wealth management income 1,082 1,091 1,139 1,230 1,328 Insurance income Ordinary share capital 24,049 31,334 32,722 34,150 35,607 Total operating income 1,406 1,567 1,244 1,343 1,450 Other equity instruments 4,331 3,317 3,317 3,317 3,317 Wealth management expense Reserves ,662-5,662-5,662-5,662 Other expenses Retained profits 20,377 20,943 21,171 22,615 24,396 Net profit before tax Minority interests Corporate tax expense Total shareholders' equity 47,908 49,951 51,567 54,439 57,676 Investment experience NPAT (cash basis) Total sh. equity & liabs. 883, , , ,180 1,008,276 FUA 158, , , , ,350 WANOS - statutory (m) 2,330 2,439 2,614 2,691 2,747 NZ Banking WANOS - cash (m) 2,387 2,498 2,676 2,753 2,809 Net interest income 1,382 1,504 1,549 1,601 1,659 Other income PROFITABILITY RATIOS Total operating income 1,831 1,938 2,007 2,078 2,157 Y/e September (pf) 2015 (pf) 2016e 2017e 2018e Operating expenses Return on assets 0.6% 0.7% 0.7% 0.7% 0.7% Impairment expenses Return on equity 12.4% 14.2% 13.9% 13.7% 13.8% Net profit before tax 1,014 1,048 1,064 1,161 1,214 Leverage ratio 4.5% 4.8% 5.1% 5.2% 5.2% Corporate tax expense Net interest margin 1.88% 1.82% 1.81% 1.80% 1.79% Minority interests Cost / income ratio 48% 43% 42% 42% 41% Investment experience Cost / average assets 0.92% 0.81% 0.85% 0.84% 0.83% NPAT (cash basis) Growth in operating income -9% 4% 3% 5% 5% Loans 57,368 61,909 64,037 66,240 68,890 Growth in operating expenses -5% -7% 3% 5% 3% Deposits 39,463 41,619 43,259 45,397 47,899 Jaws -5% 11% n/m 1% 2% Other IBL Effective tax rate 31% 29% 30% 30% 30% ASSET QUALITY Y/e September (pf) 2015 (pf) 2016e 2017e 2018e Impairment expense / GLA 0.15% 0.14% 0.19% 0.22% 0.23% Impairment expense / RWA 0.20% 0.21% 0.26% 0.30% 0.32% Total provisions ($m) 3,118 3,520 3,983 4,193 4,417 Total provisions / RWA 0.85% 1.00% 0.99% 0.99% 0.99% Indiv ass prov / gross imp assets 33% 31% 31% 31% 31% IBL / IEA 100% 105% 103% 102% 102% Total provisions + GRCL / RWA 1.00% 0.99% 0.99% 0.99% 0.99% SOURCE: BELL POTTER SECURITIES ESTIMATES Page 9

10 Recommendation structure Buy: Expect >15% total return on a 12 month view. For stocks regarded as Speculative a return of >30% is expected. Research Team Staff Member TS Lim Sam Haddad John O Shea Title/Sector Head of Research Phone tslim shaddad joshea Hold: Expect total return between -5% Chris Savage csavage and 15% on a 12 month view Jonathan Snape jsnape Sell: Expect <-5% total return on a 12 month view Sam Byrnes John Hester Tanushree Jain Healthcare Healthcare/Biotech sbyrnes jhester tnjain Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet. Such investments may carry an Financials TS Lim Lafitani Sotiriou Resources Peter Arden David Coates Quantitative Tim Piper Hamish Murray Banks/Regionals Diversified Resources Resources Associate Analyst Associate Analyst tslim lsotiriou parden dcoates tpiper hmurray exceptionally high level of capital risk and volatility of returns. Bell Potter Securities Limited ACN Level 38, Aurora Place 88 Phillip Street, Sydney 2000 Telephone The following may affect your legal rights. Important Disclaimer: This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client s financial situation, particular needs and investment objectives ( relevant personal circumstances ), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arraignment with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person. Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document. ANALYST CERTIFICATION Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to Bell Potter, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Page 10

National Australia Bank (NAB)

National Australia Bank (NAB) 6 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $30.39 Target (12 months) $32.50 (previously $30.00) Expected Return Capital growth

More information

ANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES

ANZ Bank (ANZ) Unquestionably strong 1Q17. Healthy Jaws, safe to go back in the water SOURCE: BELL POTTER SECURITIES ESTIMATES 17 February 2017 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 ANZ Bank (ANZ) Unquestionably strong 1Q17 Recommendation Buy (Hold) Price $30.21 Target (12 months) $33.25 (previously

More information

Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions

Perpetual (PPT) Oversold, upgrade to Buy. Over 6% yield, with upside in market rally. Quarterly highlights. Earnings revisions 16 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation TS Lim 612 8224 2810 Perpetual (PPT) Oversold, upgrade to Buy Recommendation Buy (Hold) Price $42.09 Target (12 months) $47.50 (previously

More information

Platinum Asset Management (PTM)

Platinum Asset Management (PTM) 24 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Recommendation Hold (unchanged) Price $5.10 Target (12 months) $4.90

More information

ANZ Banking Group (ANZ)

ANZ Banking Group (ANZ) 1 May 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $27.47 Target (12 months) $30.20 (unchanged) GICS Sector Banks Expected Return Capital

More information

Commonwealth Bank (CBA)

Commonwealth Bank (CBA) 10 February 2016 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Commonwealth Bank (CBA) Ordeal and triumph Recommendation Buy (unchanged) Price $74.20 Target (12 months) $83.50 (previously

More information

Auswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps

Auswide Bank (ABA) There are no tricks in plain and simple faith. 24 August : Underlying NPAT $17m, final dividend 18cps 24 August 2018 TS Lim 612 8224 2810 Authorisation Tim Piper 612 8224 2825 Recommendation Buy (unchanged) Price $5.71 Target (12 months) $6.20 (previously $5.80) GICS Sector Banks Expected Return Capital

More information

Adacel Technologies (ADA)

Adacel Technologies (ADA) 9 November 2018 Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Adacel Technologies (ADA) Bad, but not that bad Recommendation Buy (unchanged) Price $0.88 Target (12 months) $1.50 (previously

More information

OneVue Holdings (OVH)

OneVue Holdings (OVH) 24 April 2018 Analyst Lafitani Sotiriou 613 9235 1668 Authorisation Peter Arden 613 9235 1833 OneVue Holdings (OVH) Restructured and focused Recommendation Buy (unchanged) Price $0.745 Target (12 months)

More information

OneVue Holdings (OVH)

OneVue Holdings (OVH) 7 August 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 OneVue Holdings (OVH) FY17 result to show cost-out progress Recommendation

More information

BWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES

BWX Limited (BWX) SOURCE: BELL POTTER SECURITIES ESTIMATES 9 February 2017 Analyst John O'Shea 613 9235 1633 Authorisation John Hester 612 8224 2871 Recommendation Buy (unchanged) Price $4.80 Target (12 months) $5.73 (unchanged) Expected Return Capital growth

More information

Nanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES

Nanosonics (NAN) Preparing for new international markets. Maintain Hold, price target amended to $3.20 SOURCE: BELL POTTER SECURITIES ESTIMATES 21 February 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) Growth Slowly Emerging In Europe Recommendation Hold (unchanged) Price $2.80 Target (12 months) $3.20

More information

Mayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17.

Mayne Pharma (MYX) Yet Another Transformational Acquisition. FY16 Earnings Confirmed. The company did not provide guidance in respect of FY17. 29 June 2016 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Mayne Pharma (MYX) Merger Fallout Creates Opportunity Recommendation Buy (unchanged) Price $1.485 Target (12 months) $1.89

More information

SurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns

SurfStitch (SRF) Shaping the Surf industry. Acquisition in Product drives credibility. however we have some concerns 26 November 20 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 SurfStitch (SRF) Shaping the Surf industry Recommendation Buy (unchanged) Price $2.06 Target (12 months) $2.65 (previously

More information

Challenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES

Challenger (CGF) Expanding the potential. A broader and more robust business emerging. Earnings revisions SOURCE: BELL POTTER SECURITIES ESTIMATES 14 February 2017 Analyst Lafitani Sotiriou 613 9235 1668 Associate Analyst James Filius 613 9235 1612 Authorisation TS Lim 612 8224 2810 Challenger (CGF) Expanding the potential Recommendation Buy (unchanged)

More information

Nanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES

Nanosonics (NAN) Summary of 2Q17 Cash Flows SOURCE: BELL POTTER SECURITIES ESTIMATES 16 January 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Nanosonics (NAN) US Market Continues To Expand Recommendation Hold (unchanged) Price $3.16 Target (12 months) $3.28

More information

Osprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55

Osprey (OSP) FY16 EBITDA Loss In Line. OSP has US$21.8m of cash as at 31 December Maintain Buy Rating And Valuation at $0.55 27 February 2017 Analyst John Hester 612 8224 2871 Authorisation Tanushree Jain 612 8224 2849 Recommendation Buy (unchanged) Price $0.415 Valuation $0.55 (unchanged) Risk Speculative GICS Sector Healthcare

More information

IPH Limited (IPH) Buy at the bottom

IPH Limited (IPH) Buy at the bottom 29 March 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 IPH Limited (IPH) Buy at the bottom Recommendation Buy (unchanged) Price $4.76 Target (12 months) $7.90 (unchanged) Expected

More information

Fortescue Metals Group Ltd (FMG)

Fortescue Metals Group Ltd (FMG) 3 March 2017 Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Fortescue Metals Group Ltd (FMG) All about the iron ore price Recommendation Sell (unchanged) Price $6.62 Target

More information

Aeon Metals Limited (AML)

Aeon Metals Limited (AML) Analyst David Coates 612 8224 2887 Authorisation Stuart Howe 613 9235 1856 Speculative See key risks on Page 4 Speculative securities may not be suitable for retail clients 22 March 2019 Aeon Metals Limited

More information

Peet Bonds (PPCHA) A yield uplift from fixed rate senior debt

Peet Bonds (PPCHA) A yield uplift from fixed rate senior debt 4 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 (PPCHA) Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code Peet PPCHA Face value $100 Estimated

More information

Cyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES

Cyclopharm (CYC) Entry to US market inching closer. Maintain Buy Recommendation SOURCE: BELL POTTER SECURITIES ESTIMATES Analyst John Hester 612 8224 2871 Cyclopharm (CYC) 5 March 2018 Speculative See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.

More information

Premier Investments (PMV)

Premier Investments (PMV) 16 March 2018 Analyst Sam Haddad 612 8224 2819 Authorisation Tim Piper 612 8224 2825 Premier Investments (PMV) Key growth pillars all strong Recommendation Buy (unchanged) Price $15.27 Target (12 months)

More information

7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date

7.0% fully franked yield (expected 10.0% gross): Fixed until Nov 2018 reset date 6 July 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 William Spraggett 613 9235 1733 Whitefield Resettable Preference Shares (WHFPB) Authorisation John Gleeson 612 9255 7220

More information

Westgold Resources (WGX)

Westgold Resources (WGX) 3 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.36 Target (12 months) $2.15 (unchanged) Expected Return Capital growth

More information

Macquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS

Macquarie Group Capital Notes 2 (MQGPB) * MANDATORY CONVERSION IS SUBJECT TO SATISFYING THE MANDATORY CONVERSION CONDITIONS 23 November 2015 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Macquarie Group Capital Notes 2 (MQGPB) TS Lim 612 8224 2810 Fixed Interest Issue overview Issuer Issue

More information

Metals X Limited (MLX)

Metals X Limited (MLX) 16 July 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.655 Target (12 months) $0.95 (previously $0.98) Expected Return Capital growth

More information

Breaker Resources NL (BRB)

Breaker Resources NL (BRB) David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Speculative See key risks on Page 6. Speculative securities may not be suitable for retail clients 8 February 2019 Breaker NL (BRB) More

More information

Metals X Limited (MLX)

Metals X Limited (MLX) 5 September 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.515 Target (12 months) $0.90 (previously $0.95) Expected Return Capital

More information

Ride the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call

Ride the recovery. Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call 17 May 2016 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code BELL POTTER SECURITIES LIMITED ACN

More information

National Australia Bank

National Australia Bank AUSTRALIA NAB AU Price (at 08:23, 03 Jul 2012 GMT) Outperform A$23.68 Volatility index Low 12-month target A$ 27.66 12-month TSR % +24.9 Valuation A$ - DCF (WACC 12.6%, beta 1.0, ERP 5.0%, RFR 5.8%) 25.14

More information

Talisman Mining Ltd (TLM)

Talisman Mining Ltd (TLM) Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.41 Valuation $0.88 (previously $1.00) Risk Speculative Expected Return Capital growth

More information

Value at the top end. Figure 1: Trading margins on debt and equity securities

Value at the top end. Figure 1: Trading margins on debt and equity securities 17 February 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Steve Goldberg 612 8224 2809 Westpac Convertible Preference Shares (WBCPC) Fixed Interest Issue overview

More information

Metals X Limited (MLX)

Metals X Limited (MLX) 19 April 2018 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $0.76 Target (12 months) $0.98 (previously $1.00) Expected Return Capital growth

More information

Tech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e

Tech Sector. Updated key sells: None. Company Ticker Share price at Market Year end 22-Mar-17 cap FY17a/CY17e FY18e/CY18e FY17a/CY17e FY18e/CY18e 22 March 2017 Analyst Chris Savage 612 8224 2835 Authorisation TS Lim 612 8224 2810 Tech Sector Key picks unchanged: IRI, APX, ADA & IFM Stock Price Target Rating ADA $2.37 $3.25 Buy ALU $7.41 $7.90 Hold

More information

Osprey Medical (OSP)

Osprey Medical (OSP) 18 October 2017 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Osprey Medical (OSP) Harvey and Irma Curtail Growth Speculative See key risks on Page 5 and Biotechnology Risk Warning

More information

Fortescue Metals Group (FMG)

Fortescue Metals Group (FMG) 30 October 2015 Analyst David Coates 612 8224 2887 Authorisation John Hester 612 8224 2871 Recommendation Buy (Hold) Price $2.09 Target (12 months) $2.40 (unchanged) Expected Return Capital growth 14.8%

More information

Bendigo and Adelaide Bank

Bendigo and Adelaide Bank AUSTRALIA BEN AU Price (at CLOSE#, 17 Aug 2012) Neutral A$8.69 Volatility index Low 12-month target A$ 9.28 12-month TSR % +14.0 Valuation - DCF (WACC 12.1%) A$ 8.28 GICS sector Banks Market cap A$m 3,447

More information

Galaxy Resources Ltd (GXY)

Galaxy Resources Ltd (GXY) Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $1.835 Valuation $3.35 (unchanged) -------------- Risk Speculative Expected Return Capital

More information

Australian Banks. Funding markets open for now

Australian Banks. Funding markets open for now AUSTRALIA Weekly performance 4% 2% % -2% -4% -6% -8% -1% Source: IRESS, August 212 Rolling monthly performance 8% 6% 4% 2% % -2% -4% -6% Source: IRESS, August 212 Rolling yearly performance % 15% 5% -5%

More information

Galaxy Resources Ltd (GXY)

Galaxy Resources Ltd (GXY) 27 March 2018 Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Galaxy Resources Ltd (GXY) Mt Cattlin doing what it is meant to Recommendation Buy Price $3.16 Price Target $4.75

More information

Figure 1: ASX listed debt redemptions Figure 2: Trading margins on debt and equity securities

Figure 1: ASX listed debt redemptions Figure 2: Trading margins on debt and equity securities 8 February 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation (NABPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue ASX code NAB NABPE Face value $100

More information

Premier Investments (PMV)

Premier Investments (PMV) 4 April 2017 Analyst Sam Haddad 612 8224 2819 Authorisation TS Lim 612 8224 2810 Premier Investments (PMV) The Myers touch Recommendation Buy (unchanged) Price $14.20 Target (12 months) $17.65 (previously

More information

Westgold Resources (WGX)

Westgold Resources (WGX) 7 February 2017 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $2.25 Target (12 months) $2.60 Expected Return Capital growth 15.6% Dividend

More information

Earnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation

Earnings and target price revision. Price catalyst. Catalyst: 1H14 result in February Action and recommendation AUSTRALIA CBA AU Price (at 06:10, 10 Sep 2013 GMT) Neutral A$73.63 Valuation A$ - DCF (WACC 10.3%, beta 1.0, ERP 5.0%, RFR 5.5%) 50.40 12-month target A$ 66.15 12-month TSR % -5.0 Volatility Index Low

More information

Breaker Resources NL (BRB)

Breaker Resources NL (BRB) Analyst David Coates 612 8224 2887 Authorisation Peter Arden 613 9235 1833 Recommendation Buy (unchanged) Price $0.315 Valuation $0.96 (previously $1.30) Risk Speculative GICS Sector Materials Expected

More information

ANZ Bank. What execution risk? Earnings and target price revision. Price catalyst. Catalyst: 1Q17 Trading update, February 2017.

ANZ Bank. What execution risk? Earnings and target price revision. Price catalyst. Catalyst: 1Q17 Trading update, February 2017. AUSTRALIA ANZ AU Price (at 09:15, 18 Jan 2017 GMT) Neutral A$30.11 Valuation A$ 30.69- - Sum of Parts/GG 31.47 12-month target A$ 31.00 12-month TSR % +8.4 Volatility Index Low/Medium GICS sector Banks

More information

Australian Banks. Money Talks vertically challenged AUSTRALIA. Inside. Majors average short positions and banks index

Australian Banks. Money Talks vertically challenged AUSTRALIA. Inside. Majors average short positions and banks index Jun- Dec- Jun- Dec- Jun- Dec- Jun-1 Dec-1 Jun-11 Dec-11 Jun-1 Dec-1 Jun-1 Dec-1 Jun-1 Dec-1 Jun- Dec- AUSTRALIA Repricing generally follows an election s Nov Aug 1 Sep 1 1-1 Source: RBA, Macquarie Research,

More information

QBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision

QBE Insurance. QBE ANZ performance: LMI vs. Excl. LMI (A$m) Source: Company data, Macquarie Research, April 16. Earnings and target price revision AUSTRALIA QBE AU Price (at 10:44, 27 Apr 2016 GMT) Neutral A$11.19 Valuation A$ - DCF (WACC 9.3%, beta 1.1, ERP 5.0%, RFR 3.8%) 11.34 12-month target A$ 12.00 12-month TSR % +12.7 Volatility Index Low/Medium

More information

David Craig CHIEF FINANCIAL OFFICER

David Craig CHIEF FINANCIAL OFFICER David Craig CHIEF FINANCIAL OFFICER 14 November 2007 Commonwealth Bank of Australia ACN 123 123 124 MORGAN STANLEY ASIA PACIFIC SUMMIT 2007 SINGAPORE Disclaimer The material that follows is a presentation

More information

Westpac Banking Corporation

Westpac Banking Corporation Westpac Banking Corporation David Morgan Chief Executive Officer March 2007 Westpac Banking Corporation at a glance Australia s first bank est. 1817 Top 50 bank globally 1 Consistent earnings growth Strong

More information

Bank of Queensland Capital Notes (BOQPE) Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call

Bank of Queensland Capital Notes (BOQPE) Figure 1: Trading margins on debt and equity securities. (prior to exchange) over BBSW Mand Conv* Call 23 November 2017 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation Bank of Queensland Capital Notes (BOQPE) TS Lim 612 8224 2810 Fixed Income Issue overview Issuer Issue

More information

Pioneer Credit (PNC)

Pioneer Credit (PNC) 23 June 2014 Analyst Sam Byrnes 612 8224 2886 Authorisation Chris Savage 612 8224 2835 Pioneer Credit (PNC) Helping not chasing Recommendation Buy (Initiation) Price $1.55 Target (12 months) $1.80 Expected

More information

Australian Banks. Pre-Reporting Form Guide AUSTRALIA. Event. Impact. Outlook

Australian Banks. Pre-Reporting Form Guide AUSTRALIA. Event. Impact. Outlook AUSTRALIA MRE vs Consensus MQG FY15 Consensus FY15 Date Profit EPS DPS Profit EPS DPS BEN 10-Aug 439 92 67 434 92 67 CBA 12-Aug 9,289 557 420 9,116 554 419 Source: Factset, Macquarie Research, August 2015

More information

AMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation

AMP. Earnings and target price revision. No change. Price catalyst. Action and recommendation AUSTRALIA AU Price (at CLOSE#, 19 Mar 213) Underperform A$5.7 Volatility index Low 12-month target A$ 4.99 12-month TSR % +3.6 Valuation - Sum of Parts A$ 4.68 GICS sector Insurance Market cap A$m 14,855

More information

Strike Energy Ltd (STX)

Strike Energy Ltd (STX) Analyst Peter Arden 613 9235 1833 Authorisation Stuart Howe 613 9235 1782 Recommendation Buy (unchanged) Price $0.115 Valuation $0.26 (previously $0.23) Risk Speculative Expected Return Capital growth

More information

Mesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt

Mesoblast (MSB) GVHD granted Fast Track, should benefit ongoing negotiations with Mallinckrodt 7 March 2017 Analyst Tanushree Jain 612 8224 2849 Authorisation Chris Savage 612 8224 2835 Recommendation Buy (unchanged) Price $1.90 Valuation $3.22 (previously $3.17) Risk Speculative GICS Sector Pharmaceuticals

More information

Paragon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality

Paragon Care (PGC) Big Boxes, Big Opportunity. Capitalising on the burgeoning healthcare sector. Price leadership through quality 26 September 2014 Analyst John Hester 612 8224 2871 Authorisation TS Lim 612 8224 2810 Paragon Care (PGC) Big Boxes, Big Opportunity Recommendation Buy (Initiation) Price $0.33 Target (12 months) $0.38

More information

National Australia Bank

National Australia Bank AUSTRALIA NAB AU Price (at 06:10, 27 Jul 2015 GMT) Outperform A$33.91 Valuation A$ - DCF (WACC 9.6%, beta 1.0, ERP 5.0%, RFR 5.8%) 37.74 12-month target A$ 39.39 12-month TSR % +22.1 Volatility Index Low

More information

Australian Banks. If it s too good to be true AUSTRALIA. Event. Impact. Outlook. Impact of repricing and capital from additional 10% investor RWA

Australian Banks. If it s too good to be true AUSTRALIA. Event. Impact. Outlook. Impact of repricing and capital from additional 10% investor RWA CBA CBA CBA CBA AUSTRALIA Changes to lending rates (bps) bps Owner Occupier Investor P&I IO P&I IO 0 20 25 36 CBA 3 25 24 26 7 7 25 25 3 8 23 28 BEN 0 0 25 25 Source: Company data, Macquarie research,

More information

Bank Note$ Mentioned in despatches. 7 March December 2017 reporting wrap: Fundamentals sound

Bank Note$ Mentioned in despatches. 7 March December 2017 reporting wrap: Fundamentals sound 7 March 2018 Analyst TS Lim 612 8224 2810 Authorisation Chris Savage 612 8224 2835 Bank Note$ Mentioned in despatches Stock Price Target Rating ANZ $28.58 $32.50 Buy CBA $75.69 $83.90 Buy NAB $30.10 $34.20

More information

Metals X Limited (MLX)

Metals X Limited (MLX) 1 November 2016 Analyst Peter Arden 613 9235 1833 Authorisation David Coates 612 8224 2887 Recommendation Buy (unchanged) Price $1.38 Target (12 months) $2.10 (unchanged) Expected Return Capital growth

More information

Westpac 2009 Full Year Results

Westpac 2009 Full Year Results Westpac 2009 Full Year Results Gail Kelly Chief Executive Officer Westpac Banking Corporation ABN 33 007 457 141 Key areas of focus in 2009 Position the Group strongly through the GFC and economic downturn

More information

NAB 2015 Half Year Results

NAB 2015 Half Year Results 800 Bourke Street Docklands VIC 3008 AUSTRALIA www.nabgroup.com Thursday, 7 May 2015 ASX Announcement NAB 2015 Half Year Results Executing our strategy, building a stronger bank Highlights Cash earnings

More information

St George Mining Ltd (SGQ)

St George Mining Ltd (SGQ) Analyst Peter Arden 613 9235 1833 Authorisation Duncan Hughes 618 9326 7667 Recommendation Buy (unchanged) Price $0.225 Valuation $0.30 (previously $0.26) Risk Speculative Expected Return Capital growth

More information

Presentation of Full Year Results for period ended 30 June 2004

Presentation of Full Year Results for period ended 30 June 2004 Presentation of Full Year Results for period ended 30 June 2004 David Murray Chief Executive Officer Michael Cameron Chief Financial Officer 11 August 2004 www.commbank.com.au Disclaimer The material that

More information

Platinum Asset Management

Platinum Asset Management AUSTRALIA PTM AU Price (at 06:10, 11 Jul 2016 GMT) Neutral A$5.52 Valuation A$ - DCF (WACC 9.3%, beta 1.2, ERP 5.0%, RFR 3.3%) 5.19 12-month target A$ 5.36 12-month TSR % +2.6 Volatility Index Low/Medium

More information

JP Morgan Australasian Conference Edinburgh

JP Morgan Australasian Conference Edinburgh JP Morgan Australasian Conference Edinburgh Ralph Norris CHIEF EXECUTIVE OFFICER 18 September 2008 Commonwealth Bank of Australia ACN 123 123 124 Disclaimer The material that follows is a presentation

More information

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS

BUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD

More information

For personal use only

For personal use only NAB 2017 Full Year Results Summary Sarah and Justin Montesalvo Patriot Campers 2017 FINANCIAL HIGHLIGHTS $ 5,285 M Statutory net profit 99 CPS Final dividend 100% franked $ 5.3 BN Dividends declared $

More information

Ralph Norris CHIEF EXECUTIVE OFFICER

Ralph Norris CHIEF EXECUTIVE OFFICER Ralph Norris CHIEF EXECUTIVE OFFICER 27 September 2007 Commonwealth Bank of Australia ACN 123 123 124 JP MORGAN ASIA PACIFIC AUSTRALASIAN CONFERENCE 2007 EDINBURGH Disclaimer The material that follows

More information

Bendigo and Adelaide Bank

Bendigo and Adelaide Bank AUSTRALIA AU Price (at 06:17, 30 Mar 2017 GMT) Underperform A$12.03 Valuation A$ 11.48- - Sum of Parts/GG 11.71 12-month target A$ 11.50 12-month TSR % +1.2 Volatility Index Low/Medium GICS sector Banks

More information

Bank of Queensland Full year results 31 August Bank of Queensland Limited ABN AFSL No

Bank of Queensland Full year results 31 August Bank of Queensland Limited ABN AFSL No Bank of Queensland Full year results 31 August 2013 Bank of Queensland Limited ABN 32 009 656 740. AFSL No 244616. Agenda Result overview Stuart Grimshaw Managing Director and CEO Financial detail Anthony

More information

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016.

IOOF. Positive flows in 1Q17. FUM and Net Flows for September Qtr Source: Company data, Macquarie Research, Oct 2016. AUSTRALIA IFL AU Price (at 06:35, 26 Oct 2016 GMT) Outperform A$8.34 Valuation A$ - DCF (WACC 8.8%, beta 1.1, ERP 5.0%, RFR 3.3%) 8.74 12-month target A$ 9.00 12-month TSR % +14.3 Volatility Index Low/Medium

More information

Investor Discussion Pack

Investor Discussion Pack Investor Discussion Pack David Morgan, Chief Executive Officer May 2002 Disclaimer The material contained in the following presentation is intended to be general background information on Westpac Banking

More information

Figure 1: Bell Potter fair value assessment. 2.40%: July 2018 Fixed Rate Senior Bond (OTC yield 6.00%)

Figure 1: Bell Potter fair value assessment. 2.40%: July 2018 Fixed Rate Senior Bond (OTC yield 6.00%) 13 August 2012 Analysts Damien Williamson 613 9235 1958 Barry Ziegler 613 9235 1848 Authorisation John Gleeson 612 9255 7220 Fixed Interest Issue overview Issuer Issue ASX code Crown CWNHA Face value $100

More information

2009 Half Year Results. Analyst and shareholder briefing 18 February 2009

2009 Half Year Results. Analyst and shareholder briefing 18 February 2009 2009 Half Year Results Analyst and shareholder briefing 18 February 2009 Agenda Group highlights David Deverall Financial results Roger Burrows Outlook David Deverall 1 Agenda Group highlights David Deverall

More information

Investor Presentation

Investor Presentation Determined to be better than we ve ever been. Ralph Norris CHIEF EXECUTIVE OFFICER Investor Presentation 16 November 2010 Commonwealth Bank of Australia ACN 123 123 124 Disclaimer The material that follows

More information

ANZ Bank. Turning the corner? Earnings and target price revision. Price catalyst. Catalyst: 1Q17 Trading update, February 2017.

ANZ Bank. Turning the corner? Earnings and target price revision. Price catalyst. Catalyst: 1Q17 Trading update, February 2017. AUSTRALIA ANZ AU Price (at 11:16, 3 Nov 216 GMT) Outperform A$27.35 Valuation A$ 27.47- - Sum of Parts/GG 29.23 12-month target A$ 28.5 12-month TSR +1.2 Volatility Index Low/Medium GICS sector Banks Market

More information

General Insurance Note$

General Insurance Note$ 22 September 216 Analyst TS Lim 612 8224 281 Authorisation Chris Savage 612 8224 2835 General Insurance Note$ Hasta la vista El Nino Stock Price Target Rating 1. SUN $12.41 $14.25 Buy 2. IAG $5.44 $6.

More information

ANZ Bank. The Dis-Associates. Earnings and target price revision. No change. Price catalyst. Catalyst: 3Q15 Trading Update. Action and recommendation

ANZ Bank. The Dis-Associates. Earnings and target price revision. No change. Price catalyst. Catalyst: 3Q15 Trading Update. Action and recommendation AUSTRALIA ANZ AU Price (at 07:51, 03 Jul 2015 GMT) Underperform A$32.46 Valuation - DDM/PE A$ 32.52 12-month target A$ 33.91 12-month TSR % +10.0 Volatility Index Low GICS sector Banks Market cap A$m 89,752

More information

Media Presentation. Results Presentation FOR THE FULL YEAR ENDED 30 JUNE Ian Narev Chief Executive Officer. 10 February 2010

Media Presentation. Results Presentation FOR THE FULL YEAR ENDED 30 JUNE Ian Narev Chief Executive Officer. 10 February 2010 Media Presentation FOR THE FULL YEAR ENDED 30 JUNE 2012 Results Presentation Ian Narev Chief Executive Officer For the half year ended 31 December 2009 10 February 2010 Commonwealth Bank of Australia ACN

More information

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation

Challenger. Normalised margin trends expected to decline. Earnings and target price revision. Price catalyst. Action and recommendation 1H13E 2H13E 1H14E 2H14E 1H15E 2H15E AUSTRALIA CGF AU Price (at CLOSE#, 20 Aug 2012) Outperform A$3.76 Volatility index Low 12-month target A$ 4.57 12-month TSR % +26.4 Valuation - Sum of Parts A$ 4.57

More information

QV Equities Limited. Investor Update - 1 -

QV Equities Limited. Investor Update - 1 - QV Equities Limited Investor Update - 1 - March roadshow 2015 QV Equities Limited Intro & Business Update Managed by Investors Mutual Focused on Ex-20 stocks Listed 22 August 2014 Quality and experienced

More information

FY18 Results Presentation 31 July Thomas Beregi, CEO Michael Eadie, CFO

FY18 Results Presentation 31 July Thomas Beregi, CEO Michael Eadie, CFO FY18 Results Presentation 31 July 2018 Thomas Beregi, CEO Michael Eadie, CFO Leadership in the credit impaired consumer segment ANALYTICS & DISCIPLINE OPERATIONAL EXCELLENCE SUSTAINABILITY & COMPLIANCE

More information

ONEVIEW HEALTHCARE PLC

ONEVIEW HEALTHCARE PLC ONEVIEW HEALTHCARE PLC BUY 2017 Result Green Shoots Emerging Health Care Equipment & Services / Health Care Technology 28 February 2018 COMPANY UPDATE Ticker ONE Stock Price $1.900 Target Price $3.04 Forecast

More information

The Great Muddle Through. Wayne McGauley Head of Retail, IML March 2014

The Great Muddle Through. Wayne McGauley Head of Retail, IML March 2014 The Great Muddle Through Wayne McGauley Head of Retail, IML March 2014 1 Agenda Intro to IML The Great Muddle Through Investment strategy Portfolio focus for clients Summary 2 Agenda Intro to IML The Great

More information

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation

Boart Longyear. Earnings and target price revision. No change. Price catalyst. Action and recommendation AUSTRALIA BLY AU Price (at 08:01, 12 Sep 2013 GMT) Neutral A$0.50 Valuation A$ 0.71 - DCF (WACC 10.1%, beta 1.5, ERP 0.1%, RFR 0.1%, TGR 0.0%) 12-month target A$ 0.56 12-month TSR % +12.0 Volatility Index

More information

Aspire Mining Ltd (AKM)

Aspire Mining Ltd (AKM) 4 June 2012 Analyst Stuart Howe 613 9235 1782 Fred Truong 613 9235 1629 Authorisation Jonathan Snape 613 9235 1601 Aspire Mining Ltd (AKM) Ovoot PFS released Recommendation Buy (unchanged) Price $0.13

More information

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst

NIB Holdings. Lowest in 4 years still enough A$3.72 AUSTRALIA. Event. Impact. Earnings and target price revision. Price catalyst AUSTRALIA NHF AU Price (at 09:52, 02 Mar 2016 GMT) Outperform A$3.72 Valuation A$ 3.85 - DCF (WACC 8.5%, beta 1.0, ERP 5.0%, RFR 3.8%, TGR 2.5%) 12-month target A$ 4.00 12-month TSR % +11.7 Volatility

More information

IOOF Presentation. Peter Mahoney. April 2012

IOOF Presentation. Peter Mahoney. April 2012 IOOF Presentation Peter Mahoney April 2012 1 contents 1. philosophy & process 2. investment team 3. performance 4. stock insight & strategy 5. summary 6. appendices 2 1 proven investment approach the way

More information

Bendigo and Adelaide Bank

Bendigo and Adelaide Bank Bendigo and Adelaide Bank FY 2009 Results August 10, 2009 This document is a presentation of general background information about the Group s activities current at the date of the presentation. It is information

More information

1H19 RESULTS PRESENTATION

1H19 RESULTS PRESENTATION 1H19 RESULTS PRESENTATION 11 APRIL 2019 Half year ended 28 February 2019 Anthony Rose Interim CEO Matt Baxby Chief Financial Officer Anthony Rose Interim CEO 2 Niche growth, asset quality and capital remain

More information

Sigma Insight Capital Hungry Banks

Sigma Insight Capital Hungry Banks June 2015 Sigma Insight Capital Hungry Banks Summary Major Bank capital builds of approx. $40-$60bn to see EPS and DPS track sideways Rising capital intensity to place downward pressure on ROE s Payout

More information

Bank of Queensland. Macquarie Connections Australia Conference 7 May 2009

Bank of Queensland. Macquarie Connections Australia Conference 7 May 2009 Bank of Queensland 7 May 2009 Difficult environment... Our response The Environment... Going forward Economic growth slowing Unemployment rising towards 7-8%... Plan for economy to bottom in late 2010

More information

Results Presentation. Ian Narev Group Executive Business & Private Banking. UBS 10th Annual Australian Financial Services Conference 2011.

Results Presentation. Ian Narev Group Executive Business & Private Banking. UBS 10th Annual Australian Financial Services Conference 2011. DETERMINED TO BE BETTER THAN WE VE EVER BEEN. Ian Narev Group Executive Business & Private Banking UBS 10th Annual Australian Financial Services Conference 2011 Results Presentation For the half year ended

More information

This page has been left blank intentionally. Full Year Results

This page has been left blank intentionally. Full Year Results This page has been left blank intentionally. Results for announcement to the market Results for announcement to the market Report for the full year ended 30 September 30 September $m Revenue from ordinary

More information

Australian Banks. The chicken or the egg AUSTRALIA. Growth under threat... but undeniable valuation support. Inside

Australian Banks. The chicken or the egg AUSTRALIA. Growth under threat... but undeniable valuation support. Inside AUSTRALIA Inside The chicken or the egg 2 Earnings/price target changes 4 Margins outlook upside overstated Deteriorating credit quality outlook 17 Attractive valuations... but need to be brave 26 Returns

More information

Wisr Ltd (DirectMoney)

Wisr Ltd (DirectMoney) Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The

More information

National Australia Bank

National Australia Bank AUSTRALIA NAB AU Price (at 05:32, 30 Mar 2015 GMT) Outperform A$38.32 Valuation A$ - DCF (WACC 9.3%, beta 1.0, ERP 5.0%, RFR 5.8%) 38.97 12-month target A$ 40.58 12-month TSR % +11.1 Volatility Index Low

More information